96 results about "Respiratory virus" patented technology

The present disclosure relates to compositions and methods for vaccinating a subject against a variety of SARS-CoV-2 variants and other respiratory viruses, the compositions and methods involve preparing and delivering extracellular vesicles expressing on its surface an engineered spike protein, an engineered nucleocapsid protein, an engineered hemagglutinin protein, and / or an engineered respiratory syncytial virus pre-fusion or fusion (RSV F) protein. The invention also relates to compositions and methods for designing, preparing, making, formulating and / or using spike display, nucleocapsid display, hemagglutinin display and / or RSV F display vesicle vaccines, the spike display, nucleocapsid display, hemagglutinin display, and / or RSV F display vesicle vaccines are designed to elicit potent humoral and cellular immune responses against a variety of respiratory viruses and variants.

The invention relates to methods and kits for detecting a virus, e.g., a respiratory virus such as a coronavirus, in a biological sample. The invention also relates to methods and kits for detecting and / or quantifying biomarkers, e.g., antibody biomarkers against a viral antigen; inflammatory and / or tissue damage response biomarkers; and / or extracellular vesicles in response to a viral infection.

The application discloses a method for producing pectin oligosaccharides by microbial degradation of pomace and application thereof. The method comprises the following steps: adding microbacterium A5 to a culture medium containing pomace to perform fermentation to obtain a fermentation liquor, performing fractional pressing filtration and filter sterilization on the fermentation liquor, performing ethanol precipitation to extract a pectin crude product, removing protein, performing ion exchange chromatography, dialysis desalting, freeze drying and the like to purify two pectin oligosaccharides POS-1 and POS-2 with a purity greater than 95%; the pectin oligosaccharides POS-1 and POS-2 have strong scavenging capacity on hydroxyl radicals and DPPH free radicals and the capacity of inhibiting the activity of respiratory RNA viruses such as influenza virus H1N1 and respiratory syncytial virus RSV, and can be applied to medicines or health foods.

There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and / or a volume-based mean diameter, and / or a structural / particle density, that is / are similar to the weight- and / or volume-based mean diameter, and / or the structural / particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and / or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

The invention provides a Raman enhanced nano-label based on a polydopamine core-shell structure, a preparation method and application of the Raman enhanced nano-label in immunochromatography, and relates to the technical field of immunochromatography. The Raman enhanced nano-label based on the polydopamine core-shell structure sequentially comprises a PDA microsphere core, a PEI layer and a gold and silver nano-particle layer from inside to outside, the gold and silver nanoparticle layer is gold and silver nanoparticles with a core-shell structure; the gold and silver nanoparticle layer is connected with a Raman signal molecule DTNB, and a terminal carboxyl group of the Raman signal molecule DTNB is coupled with a capture antibody of an H1N1 virus or a capture antibody of an SARS-CoV-2 virus. The nano-label has colorimetric and SERS enhanced activity at the same time, has the advantages of rich hot spots, high stability, excellent optical performance and the like, is used for an immunochromatography sensor to detect two respiratory viruses at the same time, adopts qualitative and quantitative dual-mode detection, and improves the detection flexibility, sensitivity and accuracy.

The present application relates to the technical field of nucleic acid detection, in particular to a RNA pathogen chemiluminescence detection method based on nucleic acid structure and sequence characteristics. The present application provides a pathogen RNA rapid detection technology based on the reporter molecule cyclization combined with rolling circle amplification according to the secondary structure and sequence characteristics of RNA, which is suitable for high-sensitivity and high-specificity detection of RNA pathogens such as respiratory viruses. The present application innovatively combines the target structure characteristics with sequence specificity, breaks through the traditional sequence-dependent isothermal amplification technology, realizes the highly specific reporter molecule cyclization, significantly improves the detection reliability, and does not require complex instruments. After the swab sample is collected, the pathogen RNA is rapidly released by using a nucleic acid releasing agent, without complex purification steps, and the reading can be realized through a common chemiluminescence instrument, which is suitable for primary site detection.

Some aspects of the disclosure relate to vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses as well as methods of using the vaccines. Also described are combination vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses and other respiratory viruses (e.g., respiratory syncytial viruses and coronaviruses), as well as methods of using the vaccines.

Described herein are compounds, pharmaceutical compositions and methods of using these compounds and pharmaceutical compositions for treating and / or preventing conditions such as, for example, those caused by any viral family causing respiratory viral disease, including specifically coronaviruses and influenza viruses.

The invention relates to the technical field of nucleic acid detection, in particular to an RNA pathogen chemiluminescence detection method based on a nucleic acid structure and sequence characteristics. The invention provides a pathogen RNA rapid detection technology which is based on RNA secondary structure and sequence characteristic reporter molecule cyclization and is combined with rolling circle amplification, and is suitable for high-sensitivity and high-specificity detection of RNA pathogens such as respiratory viruses. Target structure characteristics and sequence specificity are creatively combined, a traditional sequence-dependent isothermal amplification technology is broken through, high-specificity reporter molecule cyclization is achieved, the detection reliability is remarkably improved, complex instruments are not needed, after swab samples are collected, pathogen RNA is rapidly released through a nucleic acid releasing agent, complex purification steps are not needed, and the method is suitable for large-scale popularization and application. And reading can be realized through a common chemiluminiscence instrument, and the method is suitable for base-level field detection.

The invention relates to a quinoline triazole compound and application thereof. The quinoline triazole compound has the structural characteristics as shown in formula I, and can effectively treat diseases caused by respiratory viruses such as influenza.

The application relates to the field of microorganism detection, in particular to a respiratory virus rapid detection kit based on ZIF-8 material and a preparation method, wherein the kit comprises a virus collecting device, an exhalation cylinder and a ZIF-8 membrane, the ZIF-8 membrane is detachably arranged in the exhalation cylinder, the ZIF-8 membrane comprises a chitosan layer, the chitosan layer is uniformly distributed with ZIF-8 material, virus particles in the exhaled gas of a tester through the exhalation cylinder are adsorbed, a sample processing device comprises a processing liquid, the processing liquid elutes and lyses the virus particles adsorbed by the ZIF-8 material distributed on the chitosan layer, and a virus processing liquid is obtained, a detection reagent is used for detecting the virus processing liquid and giving a detection result, sampling is simple and rapid, the detection can be completed without the participation of professionals, sampling efficiency is higher, and the detection sensitivity is effectively improved.

The invention belongs to the technical field of biology, and discloses a monoclonal antibody capable of simultaneously recognizing multiple pedigree of porcine reproductive and respiratory syndrome virus GP5 protein. The invention discloses a recombinant protein. The recombinant protein is formed by repeatedly connecting two short peptides in series. The GP5 protein is a basis for dividing a PRRSV pedigree, the GP5 protein is taken as a research object, two regions with relatively strong immunogenicity on amino acid of the GP5 protein are repeatedly connected in series, and the two regions are further connected in series with a tag sequence or a Foldon oligopeptide to obtain a recombinant protein. The recombinant protein is used as an immunogen, and a monoclonal antibody capable of simultaneously identifying GP5 proteins of a plurality of pedigree (including pedigree 1, pedigree 3, pedigree 5 and pedigree 8) of PRRSV is prepared and screened.

According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

Disclosed in the present invention are a compound derivative represented by formula I or an isotopically labeled compound thereof, or an optical isomer, geometric isomer, tautomer or mixture of isomer thereof, or a pharmaceutically acceptable salt thereof. On the basis of the application of a dual-protection strategy, diverse carrier fragments are introduced at the 5-hydroxyl group and hydroxylamine group of the N4-hydroxycytidine molecule to develop an N4-hydroxycytidine prodrug. Such a modification enhances the affinity for a pulmonary cell membrane (phospholipid membrane), rendering the physicochemical properties of the drug suitable for the physiological environment of lung tissue. Therefore, the compound of the present invention has a broad application prospect in the aspect of broad-spectrum anti-respiratory viruses.

The present application relates to the field of molecular biology detection, in particular to a fluorescent PCR kit and a detection method for respiratory virus detection. The present application constructs specific primer groups and probes for detecting respiratory viruses, including influenza A virus, influenza B virus, human parainfluenza virus type I, human parainfluenza virus type II, human parainfluenza virus type III, respiratory syncytial virus and metapneumovirus. Through a matching PCR system, the simultaneous detection of multiple respiratory pathogens is realized in a single-color detection channel by using the melting curve and the characteristic peak of the melting temperature as indicators. The present application at least doubles the existing fluorescent PCR detection throughput, has low cost, short time consumption, greatly improves the detection efficiency, and can be widely used for mixed detection and analysis of multiple pathogens. The detection results can be further used for assisting clinical diagnosis and treatment.

The invention relates to a method and equipment for rapidly killing respiratory viruses by spatially spraying hydroxyl free radical droplets, and the method comprises the following steps: introducing oxygen O2 into an oxygen plasma generation source, and applying high-frequency and high-voltage excitation to the oxygen plasma generation source to generate high-concentration oxygen active particles; oxygen active particle gas is injected into the jet mixer, a large number of ultra-fine bubbles are generated through the water jet cavitation effect, OH is efficiently generated at the instant high temperature and high pressure of explosion of the ultra-fine bubbles and under the action of pressure shock waves of backfilling holes, and then the OH flows into the second-stage baffling mixing and dissolving device to generate a high-concentration OH solution; the OH solution is sheared by high-pressure jet flow of the spray head to form OH liquid drops, and the liquid drops are contacted, collided, broken and spread to instantly kill pathogenic microorganisms including respiratory viruses; the intelligent control system performs real-time state sensing and intelligent control, fault diagnosis, prediction and early warning, cloud service and remote monitoring.

The invention discloses application of radix glehniae polysaccharide in preventing and treating respiratory syncytial virus, and belongs to the technical field of biological medicine. The research finds that the radix glehniae polysaccharide in the radix glehniae can play a role in inhibiting the respiratory syncytial virus and can be used as a specific active ingredient for preventing and treating the respiratory syncytial virus for the first time. The research result of the invention overcomes the technical blind area that the overall efficacy of traditional Chinese medicine components cannot be attributed to specific components, accurately positions that the radix glehniae polysaccharide can play an anti-RSV role when being independently used, and provides a new target for designing a targeted RSV inhibitor and developing a combined medication strategy covering various respiratory viruses.

A vaccine composition comprising one or more proteins expressed on the surface of a respiratory virus or bacterium and one or more pharmaceutically acceptable excipient, wherein the composition is in particulate form having a mean particle size in a range of from 2 to 50 μm. The protein is contained in the composition in its correctly folded three-dimensional structure.

The invention discloses a phoebe zhennan water-soluble extract as well as an extraction method and application thereof, and belongs to the technical field of medicine extraction. The method comprises the following steps: S1, crushing a phoebe zhennan raw material, adding 6 times of water, extracting twice, 1 hour each time, and combining filtrates; s2, concentrating the filtrate obtained in the step S1 under reduced pressure until the volume is 1: 1, standing at low temperature, and taking supernate; and S3, centrifuging the supernate obtained in S2, discarding the precipitate, concentrating under reduced pressure, and drying at low temperature to obtain the phoebe zhennan water-soluble extract. The invention discloses a phoebe zhennan water-soluble extract and an extraction method and application thereof. The phoebe zhennan water-soluble extract has efficient broad-spectrum antiviral activity and can effectively inhibit respiratory virus activity.

The utility model discloses a medical cotton swab portable storage device which comprises a main body box, an avoiding hole is formed in the top face of the main body box, medical cotton swabs used for screening and collecting respiratory viruses can be conveniently carried through a storage assembly, when the medical cotton swabs need to be used, a second baffle plate is pushed, and the medical cotton swabs can be conveniently stored. A single cotton swab can be pushed out from the interior of the main body box by pushing a pushing frame, and after the pushed-out cotton swab is taken out, a second baffle plate and the pushing frame are reset immediately, so that the other medical cotton swabs are prevented from being polluted after being in contact with other articles; the cotton swabs subjected to screening and collecting can be put into the isolation box by pulling the isolation plate, and the cotton swabs in the isolation box can be shielded and isolated by pushing the isolation plate through a fourth spring after the isolation plate is loosened, so that the situation that the cotton swabs carrying viruses make contact with other objects, and consequently secondary infection is caused is avoided.

The invention provides a sensor for multichannel respiratory virus impedance detection and a detection method thereof. The synchronous detection of four respiratory viruses by the single-electrode chip is realized by electrodepositing nano-gold particles on the surface of a screen-printed carbon electrode and constructing a carboxyl self-assembled single layer, and fixing different virus specific antibodies on the surfaces of different working electrodes by adopting EDC / NHS (Ethylene Diamine Chloride / N-Hydroxysuccinimide). And recording an electrochemical impedance spectrum by using a red oxidation-reduction probe, and carrying out quantitative analysis based on total impedance change. The method has the advantages of high sensitivity, strong specificity, short detection period, low cost, suitability for on-site rapid screening and the like.

A high-sensitivity respiratory virus rapid detection device and method, the device includes a terahertz light source system, a respiratory virus test unit and a terahertz spectrum analysis unit. Wherein the respiratory virus test unit should produce a response according to the specific virus sample in different terahertz wave band, design corresponding terahertz field enhancement structure to improve the signal-to-noise ratio of the spectrum of the sample under the excitation of terahertz wave, so that the terahertz wave can produce obvious characteristic absorption spectrum after passing through the respiratory virus test unit, improve the sensitivity of terahertz wave spectrum detection, so as to obtain better respiratory virus detection effect.

The present disclosure relates to methods for treating or preventing immune-mediated pulmonary injury (IMPI) in a subject in need thereof, the method comprising administering to the subject an anti-Type I interferon (anti-T1i) therapy that blocks the activity, function or production of Type I interferon (T1i) in the subject, wherein the anti-T1i therapy is administered to the subject infected with a respiratory virus that causes a delayed T1i response in the subject.

The invention relates to a pediatric respiratory tract infection rapid diagnosis device. By setting a clinical manifestation database of various children respiratory diseases, data can be filled into the database according to external clinical manifestations of various children under different respiratory viruses; and the specific child respiratory tract infection virus type is determined through preliminary clinical manifestation data symptom judgment and further saliva detection, so that the diagnosis rhythm is accelerated, and the diagnosis accuracy is improved.

The invention discloses a noninvasive respiratory virus aerosol enrichment detection device. The noninvasive respiratory virus aerosol enrichment detection device comprises a mouthpiece type aerosol collection interface and a rear-end filter, a thick round pipe section, a contraction conical pipe section and a thin round pipe section are sequentially connected in the blowing nozzle type aerosol collecting connector, the rear-end filter is arranged on the outer wall of the thin round pipe section in a sleeved mode, an annular protrusion is arranged on the inner wall of the middle section of the rear-end filter, and one end of the rear-end filter is fixedly connected to the outer wall of the upper end of the thin round pipe section. The tail end of the thin round pipe section abuts against the annular protrusion, the filter at the rear end is blocked by a composite activated carbon protection layer, and the upper end of the thin round pipe section is blocked by non-woven fabric; the micro-fluidic enrichment module integrated with the nano-porous detection membrane is arranged between the composite activated carbon protection layer and the non-woven fabric in the thin round pipe section, and an enriched sample output by the micro-fluidic enrichment module is communicated with the detection interface, so that a high-sensitivity detection tool is provided for prevention and control of respiratory infectious diseases, and dual requirements of timeliness and universality are met.

This application relates to the field of pharmaceutical technology, specifically disclosing a self-sampling mouthwash wash composition, a self-sampling mouthwash wash, and its application. The self-sampling mouthwash wash composition, based on the self-sampling mouthwash wash composition, comprises 0.1–2.5 wt% sodium hexadecyl sulfonate, 0.05–1.0 wt% guanidine derivative, and 0.05–1.0 wt% amino derivative. The raw materials of the self-sampling mouthwash wash include the self-sampling mouthwash wash composition. The application of the self-sampling mouthwash wash in oral self-collection of respiratory viruses. This application improves the elution ability of respiratory viruses, bacteria, and other pathogenic microorganisms in the oral cavity during self-sampling.

The invention relates to an immunogenic formulation that confers protection against respiratory viruses which comprises an attenuated recombinant strain of Bacillus Calmette and Guerin (BCG), in a concentration of between 104 109 bacteria, which expresses at least one immunogenic protein or fragment of the respiratory syncytial virus (RSV). And to the use of this immunogenic formulation to prepare a vaccine to prevent, treat, or attenuate infections of respiratory viruses, especially hRSV and / or hMPV.

This invention belongs to the field of ferret health examination technology, and particularly relates to an integrated method and device for ferret respiratory virus challenge and dynamic body fluid sampling. It includes: a base plate with a sliding groove inside, a telescopic plate slidably installed within the sliding groove, support arms fixedly installed on both sides of the base plate and the telescopic plate, an arc-shaped plate fixedly installed at the top of each support arm, a sponge pad fixedly installed on the inner side of the arc-shaped plate, a clamping plate rotatably installed on the top of the arc-shaped plate, a second sponge pad fixedly installed on the inner side of the clamping plate, a protrusion fixedly installed on the arc-shaped plate, a sliding groove inside the protrusion, symmetrically sliding limit blocks installed within the sliding groove, one end of each limit block abutting against the clamping plate, and a spring fixedly installed between the two limit blocks. This invention has a wide range of applications, allowing for rapid adjustment of the device length and support arm spacing according to the height and size of the ferret, adapting to different sizes of experimental ferrets, effectively reducing animal stress and injury, and providing convenient, safe, and reliable fixation operation.

The present invention relates to the technical field of virus monitoring, and in particular to a method for monitoring respiratory viral infectious diseases, comprising establishing a virus gene library, wherein the virus gene library stores gene sequences of multiple different respiratory viruses; collecting sound information in public places and calculating an environmental risk coefficient, extracting cough events through the sound information, calculating the virus transmission index of the public place, and allocating sampling equipment to the public places in the order of the virus transmission index for sampling; after the sampling is completed, testing the samples, comparing the test results with the gene sequences in the virus gene library to obtain the load of respiratory viruses, and calculating the risk value of the virus; the present invention extracts cough events through sound information, and the cough events can quantify the intensity of virus release behavior in the place, providing a basis for subsequent risk assessment; calculating the environmental risk coefficient and ranking them, allocating and utilizing limited medical resources, and actively sampling in places with a higher probability of transmission.

This present invention relates to the use of eicosapentaenoic acid (EPA) for treating and reducing the negative effects of respiratory virus including coronaviruses and particularly the novel coronavirus-19 (COVID-19). Notably, the eicosapentaenoic acid in the free fatty acid (EPA-FFA) form has a purity of at least has a purity of at least 90%, preferably 95% and more preferably at least 99%. Specifically, the EPA-FFA exhibits a reduction of expressed interleukins, such as IL-6, reduction in D-dimers and a reduction relating to the release of AA.